These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy. Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909 [TBL] [Abstract][Full Text] [Related]
4. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249 [TBL] [Abstract][Full Text] [Related]
5. [A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder]. Fukazawa R; Takezawa H; Tsuji Y; Noto Y; Banba M; Fujii A Rinsho Shinkeigaku; 2020 Jan; 60(1):37-40. PubMed ID: 31852868 [TBL] [Abstract][Full Text] [Related]
6. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
7. Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies. Sugiyama A; Onishi Y; Ito K; Shibuya K; Nakamura K; Oda F; Nishino I; Suzuki S; Kuwabara S Intern Med; 2021 Aug; 60(16):2671-2675. PubMed ID: 33642484 [TBL] [Abstract][Full Text] [Related]
8. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies. Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. Tian CY; Ou YH; Chang SL; Lin CM J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558 [TBL] [Abstract][Full Text] [Related]
10. [Myasthenia Gravis and Myositis(PD-1 Myopathy)]. Suzuki S Gan To Kagaku Ryoho; 2020 Feb; 47(2):219-223. PubMed ID: 32381950 [TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis with inflammatory myopathy without elevation of creatine kinase. Kanbayashi T; Tanaka S; Hatanaka Y; Uchio N; Shimizu J; Sonoo M Neuromuscul Disord; 2021 Jun; 31(6):570-573. PubMed ID: 34016494 [TBL] [Abstract][Full Text] [Related]
12. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Nguyen BH; Kuo J; Budiman A; Christie H; Ali S Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019 [TBL] [Abstract][Full Text] [Related]
20. [Detection of immune complexes in the sera and around the muscle fibers in a case of myasthenia gravis and polymyositis]. Shimada K; Koh CS; Tsukada N; Shoji S; Yanagisawa N Rinsho Shinkeigaku; 1989 Apr; 29(4):432-5. PubMed ID: 2533018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]